CD70-CAR-NK Cell Therapy(Second Affiliated Hospital School Of Zhejiang University School Of Medicine)

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameCD70-CAR-NK Cell Therapy(Second Affiliated Hospital School Of Zhejiang University School Of Medicine)
Drug Alias NameCord Blood-derived CD70-targeting CAR-NK Cell Therapy(Second Affiliated Hospital School Of Zhejiang University School Of Medicine)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNatural killer cell replacementsCD70 antigen modulators
TargetsCD70 antigen
Therapy Area/IndicationsLymphoma, T-CellLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSecond Affiliated Hospital School Of Zhejiang University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital School Of Zhejiang University School Of Medicine
Inactive CompaniesN/A
Active IndicationsLymphoma, T-CellLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A